Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Inovio, Wistar Institute ink deal for DNA-based products
May 2016
SHARING OPTIONS:

PLYMOUTH MEETING, Pa.—A series of collaborative research agreements have been announced between Inovio Pharmaceuticals Inc. and the Wistar Institute focused on preventive and therapeutic DNA-based immunotherapy applications and products for cancers and infectious diseases developed by Dr. David B. Weiner and his lab at Wistar. Inovio will gain the exclusive right to in-license new intellectual property developed under this collaboration. This deal will not affacted Inovio’s license agreements for intellectual property developed at UPenn.
 
“This new agreement with Wistar starts a whole new chapter of Inovio’s R&D leadership in one of the most important emerging medical technologies: DNA-based immunotherapies. We congratulate Dr. Weiner with respect to his multiple new roles at Wistar and the significantly expanded lab and resources available to him to continue pursuing his life’s passion. We look forward to a long and fruitful relationship with this eminent institution to continue advancing cutting-edge DNA-based immunotherapies and DNA-based monoclonal antibody technology,” said Inovio President and CEO Dr. J. Joseph Kim.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.